Changing the pathophysiology of solid tumours: The potential of TNF and other vasoactive agents

References

• Jain RK. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570–576
   PubMed Web of Science ®Google Scholar
• Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429–437
   PubMed Web of Science ®Google Scholar
• Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–632
   PubMed Web of Science ®Google Scholar
• Benckhuijsen C, Kroon BB, Van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157–163
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, Benckhuijsen C, Van Geel AN, Albus-Lutter CE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64: 616–621
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224–231
   PubMedGoogle Scholar
• Rossi CR, Mocellin S, Pilati P, Foletto M, Nitti D, Lise M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: State of the art and future trends. J Immunother 2003; 26: 291–300
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, Van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990–2994
   PubMed Web of Science ®Google Scholar
• Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185: 555–564
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Manusama ER, ten Hagen TLM. Regional application of TNF alpha in the treatment of cancer: A preclinical-clinical interactive program. J Inflamm 1995; 47: 104–113
   PubMedGoogle Scholar
• Hagen TLM, Eggermont AMM, Lejeune FJ. TNF is here to stay—revisited. Trends Immunol 2001; 22: 127–129
   PubMed Web of Science ®Google Scholar
• Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997; 4: 64–69
   PubMed Web of Science ®Google Scholar
• de Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AMM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000–1003
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Kroon BB, van de Merwe SA, Klaase JM, Broekmeyer-Reurink MP, van Slooten GW, Nieweg OE, van der ZJ, van Dongen JA. Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: A pilot study. Eur Surg Res 1996; 28: 235–244
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Slooten GW, van Dongen JA, van de Merwe SA, van der ZJ. Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutaneous oxygen tension: A pilot study. J Invest Surg 1994; 7: 249–258
   PubMedGoogle Scholar
• de Wilt JHW, Manusama ER, van Tiel ST, Van Ijken MGA, ten Hagen TLM, Eggermont AMM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80: 161–166
   PubMed Web of Science ®Google Scholar
• Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408–414
   PubMed Web of Science ®Google Scholar
• Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, Fiers W, ten Hagen TL. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004; 109: 442–448
   PubMed Web of Science ®Google Scholar
• ten Hagen TLM, Van Der Veen AH, Nooijen PTGA, van Tiel ST, Seynhaeve ALB, Eggermont AMM. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000; 87: 829–837
   PubMed Web of Science ®Google Scholar
• Friedl J, Turner E, Alexander HR, Jr. Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: Evidence for disruption of vascular integrity via VE-cadherin down-regulation. Int J Oncol 2003; 23: 611–616
   PubMed Web of Science ®Google Scholar
• Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: Preclinical studies. J Natl Cancer Inst 2004; 96: 1603–1610
   PubMed Web of Science ®Google Scholar
• Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005; 65: 4300–4308
   PubMed Web of Science ®Google Scholar
• Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989; 37: 77–104
   PubMed Web of Science ®Google Scholar
• Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996; 74: 533–536
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145–147
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671–680
   PubMed Web of Science ®Google Scholar
• Eikenes L, Tari M, Tufto I, Bruland OS, de Lange DC. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer 2005; 93: 81–88
   PubMed Web of Science ®Google Scholar